IPF Research

See below for the latest in research news related to Idiopathic Pulmonary Fibrosis (IPF). This is where the PFF will share relevant news articles, press releases, and study results in the field of IPF.

The pulmonary fibrosis treatment landscape: An interview with an expert
- by Brian Buntz
- Mar 17, 2021
Full story: The pulmonary fibrosis treatment landscape: An interview with an expert
Genentech’s Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition
- by Kelsey Overberg
- Mar 5, 2021
Full story: Genentech’s Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition
CR Pharma NIP292 tablets received Orphan Drug Designation issued by FDA
- by Kelsey Overberg
- Feb 16, 2021
Full story: CR Pharma NIP292 tablets received Orphan Drug Designation issued by FDA
$22M NIH Grant Supports Precision Medicine for Pulmonary Fibrosis
- by Health IT Analytics
- Feb 10, 2021
Full story: $22M NIH Grant Supports Precision Medicine for Pulmonary Fibrosis
Driving research and awareness of pulmonary fibrosis: Pulmonary Fibrosis Foundation is leading the path to a cure
- by American Journal of Physiology | Lung Cellular and Molecular Physiology
- Feb 10, 2021
Full story: Driving research and awareness of pulmonary fibrosis: Pulmonary Fibrosis Foundation is leading the path to a cure
Pulmonary Fibrosis Foundation Announces New Sponsorship by United Therapeutics
- by Newswire
- Feb 10, 2021
Full story: Pulmonary Fibrosis Foundation Announces New Sponsorship by United Therapeutics
Spotlight on the Impact of Precision Medicine in Clinical Trial Development
- by ACRPtv
- Feb 10, 2021
Full story: Spotlight on the Impact of Precision Medicine in Clinical Trial Development
Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
- by Kelsey Overberg
- Feb 10, 2021
Full story: Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19
- by Kelsey Overberg
- Feb 5, 2021
Full story: Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
- by Kelsey Overberg
- Feb 5, 2021
Full story: Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
- by Kelsey Overberg
- Feb 5, 2021
Full story: Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—The Science of Safety and Effectiveness
- by Kelsey Overberg
- Feb 5, 2021
Full story: FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—The Science of Safety and Effectiveness
Clinical Trial Will Evaluate Saracatinib in Idiopathic Pulmonary Fibrosis
- by Kelsey Overberg
- Feb 5, 2021
Full story: Clinical Trial Will Evaluate Saracatinib in Idiopathic Pulmonary Fibrosis
US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
- by Kelsey Overberg
- Feb 5, 2021
Full story: US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
First Patient Enrolls In PRECISIONS Study For Treatment Of Idiopathic Pulmonary Fibrosis
- by Kelsey Overberg
- Jan 11, 2021
Full story: First Patient Enrolls In PRECISIONS Study For Treatment Of Idiopathic Pulmonary Fibrosis
Phase 3 trial of Novavax investigational COVID-19 vaccine opens
- by Kelsey Overberg
- Dec 29, 2020
Full story: Phase 3 trial of Novavax investigational COVID-19 vaccine opens
FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine
- by Kelsey Overberg
- Dec 21, 2020
Full story: FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
- by Kelsey Overberg
- Dec 18, 2020
Full story: Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
- by Kelsey Overberg
- Dec 18, 2020
Full story: Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
- by Kelsey Overberg
- Dec 18, 2020
Full story: Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

Book a PFF Ambassador for your event. Call 844.TalkPFF >

Life with PF

Our Role

Get Involved

Ways to Give

Medical Community

Sponsors and Exhibitors

The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program®.

PRIVACY POLICY TERMS OF USE

© 2021 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter

PRIVACY POLICY TERMS OF USE

© 2021 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter
Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation.